TGTX Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.15 |
| 52 Week High | US$36.50 |
| 52 Week Low | US$12.26 |
| Beta | 2.19 |
| 11 Month Change | 27.82% |
| 3 Month Change | 27.66% |
| 1 Year Change | 145.86% |
| 33 Year Change | 22.59% |
| 5 Year Change | 298.85% |
| Change since IPO | 2,641.46% |
Recent News & Updates
Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05Recent updates
Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Shareholder Returns
| TGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.7% | -6.5% | -1.0% |
| 1Y | 145.9% | 14.6% | 30.3% |
Return vs Industry: TGTX exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: TGTX exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TGTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TGTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 319 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| TGTX fundamental statistics | |
|---|---|
| Market cap | US$4.35b |
| Earnings (TTM) | -US$14.36m |
| Revenue (TTM) | US$264.79m |
16.9x
P/S Ratio-311.2x
P/E RatioIs TGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TGTX income statement (TTM) | |
|---|---|
| Revenue | US$264.79m |
| Cost of Revenue | US$30.94m |
| Gross Profit | US$233.85m |
| Other Expenses | US$248.21m |
| Earnings | -US$14.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 88.31% |
| Net Profit Margin | -5.42% |
| Debt/Equity Ratio | 127.3% |
How did TGTX perform over the long term?
See historical performance and comparison